IP Verse

A Stable Composition Comprising Pthrp And Uses Thereof - EP2957278

The patent EP2957278 was granted to Ipsen Pharma on May 17, 2017. The application was originally filed on Oct 3, 2007 under application number EP15176548A. The patent is currently recorded with a legal status of "Revoked".

EP2957278

IPSEN PHARMA
Application Number
EP15176548A
Filing Date
Oct 3, 2007
Status
Revoked
Nov 2, 2018
Grant Date
May 17, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ISENBRUCK BOSL HORSCHLERFeb 19, 2018RIPPELADMISSIBLE
TEVA PHARMACEUTICALSFeb 16, 2018D YOUNGADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP0679088
OPPOSITIONEP1079803
OPPOSITIONUS2002107200
OPPOSITIONUS6544949
OPPOSITIONUS6583114
OPPOSITIONWO03105772
OPPOSITIONWO9502610
OPPOSITIONWO9640775
OPPOSITIONWO9912561
SEARCHUS2005282749
SEARCHWO03105772

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Allgemeine und spezielle Pharmakolo- gie und Toxikologie, page 65-
OPPOSITION- "A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005", Ipsen, (20070917), XP055465620-
OPPOSITION- "A major pharmaceutical company has taken an exclusive option to BA 058, a compound licensed by Ipsen to Radius in 2005", Ipsen, (20170917), URL: https://www.ipsen.com/media/press-relases/a-major-pharmaceutical-company-has-taken-an-exclusive-option-to-ba058-a-compound-licensed-by-ipsen-to-radius-in-2005/, XP055465620-
OPPOSITION- "Chapter 5 - Formulation Development", BONTEMPO JOHN A, Development of Biopharmaceutical Parenteral Dosage Forms, (19970000), pages 109 - 142, ISBN 978-0-8247-9981-6, XP055465975-
OPPOSITION- CULLER et al., "poster presentation and corresponding abstract No. M460", Journal of Bone and Mineral Research, (20010000), vol. 16, no. S1, pages S1 - S390-
OPPOSITION- DONG et al., "Highly Potent Analogs of Human Parathyroid Hormone and Human Parathyroid Hormone-Related Protein", Peptides: The Wave of the Future, (20010000), pages 668 - 669, XP055465601-
OPPOSITION- "Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", FDA Guidance for Industry, (20050700), pages 1 - 27, XP055294866-
OPPOSITION- FOX, "Developments in parathyroid hormone and related peptides as bone-formation agents", Current Opinion in Pharmacology, (20020000), vol. 2, pages 338 - 344, XP055467615-
OPPOSITION- LEGRAND et al., "A Novel PTHrP Analog, Increases Bone Formation But Not Bone Resorption Histomorphometric Parameters in Old Ovariectomized Osteopenic Cynomolgus Monkeys", Am. Soc. Bone Mineral Res . 23rd Annual Meeting, (20010000), page S539, XP055465612-
OPPOSITION- LEGRAND et al., "A Novel PTHrP Analog, Increases Bone Formation But Not Bone Resorption Histomorphometric Parameters in Old Ovariectomized Osteopenic Cynomolgus Monkeys", Journal of Bone and Mineral Research , 2001 , 23rd Annual Meeting, (20010000), XP055465612-
OPPOSITION- LEGRAND et al., "A Novel PTHrP Analog, Restores In Vivo Spinal Bone Mineral Density in Old Ovariectomized Osteopenic Cynomolgus Monkeys", 23rd Annual Meeting Am. Soc. Bone Mineral Res., (20011000), XP055465605-
OPPOSITION- LEGRAND et al., "A Novel PTHrP Analog, Restores In Vivo Spinal Bone Mineral Density in Old Ovariectomized Osteopenic Cynomolgus Monkeys", Journal of Bone and Mineral Research , 2001 , 23rd Annual Meeting, (20011001), XP055465605-
OPPOSITION- "Radius Appoints Louis O'Dea Senior Vice President and Chief Medical Officer", Evaluate, (20060400), XP055465615-
OPPOSITION- "Radius Presents Positive Results from Phase IB Clinical Trial of BA 058 and Preclinical Study of RAD1901 at the Endocrine Society 2007 Annual Meeting", evaluate group, (20070608), pages 1 - 2, XP055467616-
OPPOSITION- PLOTKIN et al., "Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: Potential as an anabolic therapy for osteoporosis", Journal of Clinical Endocrinology and Metabolism, (19980000), vol. 83, no. 8, pages 2786 - 2791, XP002530375

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents